Cogent Biosciences, Inc. (COGT)

Market Cap	5.13B
Revenue (ttm)	n/a
Net Income (ttm)	-294.37M
Shares Out	152.13M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,488,720
Open	33.63
Previous Close	33.54
Day's Range	33.20 - 34.58
52-Week Range	3.72 - 36.29
Beta	0.64
Analysts	Buy
Price Target	28.08 (-16.8%)
Earnings Date	Nov 3, 2025

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and sel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 29, 2018
• Employees: 205
• Stock Exchange: NASDAQ
• Ticker Symbol: COGT
• Website: https://www.cogentbio.com

Analyst Summary

According to 13 analysts, the average rating for COGT stock is "Buy." The 12-month stock price target is $28.08, which is a decrease of -16.80% from the latest price.

Price Target

$28.08

(-16.80% downside)

Analyst Consensus: Buy